Surgery represents the only chance of cure for patients with gastroesophageal adenocarcinoma; however, surgery alone does not cure most patients. Over the past decade, several multimodality adjunctive treatments have improved survival for patients with operable gastroesophageal adenocarcinoma who are undergoing surgical resection; these include peri-operative chemotherapy, neoadjuvant chemoradiotherapy, adjuvant chemotherapy and adjuvant chemoradiotherapy. More recently, the results of several large randomised trials are leading to a shift in the peri-operative treatment of gastroesophageal cancer, away from anthracycline-based and towards taxane-based chemotherapy regimens. Emerging data support an increased focus on patients who are at high risk for poor operative outcomes such as R1 resection, and on patients who are at high risk for relapse following surgery such as those with lymph node metastases (N1þ). Future developments may include use of fluorodeoxyglucose-positron emission tomography to inform a switch to non-cross resistant chemotherapy pre-operatively and substitution of alternative treatments for chemotherapy in high risk post-operative node positive patients. Conversely, in molecularly selected subgroups such as microsatellite unstable gastroesophageal cancer, peri-operative or adjuvant chemotherapy may not be helpful, and treatments such as immunotherapy may be considered. In this review, the most upto-date clinical trials and translational research in the field of operable gastroesophageal cancer are discussed; with a focus on how best to risk stratify patients with operable disease for peri-operative treatment plus surgery, and how novel therapies might be integrated into standard treatments in order to improve survival outcomes in this patient group.
Introduction
Gastric cancer remains one of the leading causes of cancer-related deaths worldwide, with an estimated 753 000 deaths per annum [1] . Although gastric cancer incidence has decreased globally, the incidence of oesophageal adenocarcinoma tumours has concomitantly risen rapidly in Western countries [2] . Following surgical resection survival rates are low with surgery alone even for relatively early tumours (e.g. <50% for T2N0, stage II oesophageal and GOJ adenocarcinoma) [3] . Peri-operative strategies that improve survival for patients with locally advanced resectable gastric, oesophageal and GOJ cancer include perioperative chemotherapy, neoadjuvant chemoradiotherapy and adjuvant chemotherapy or chemoradiation [4] [5] [6] [7] [8] [9] . There is significant locoregional geographic variability in treatment preferences, and operable gastric and gastroesophageal cancers remains one of the few solid tumours for which there is no single globally accepted standard of care [10] [11] [12] [13] [14] . One reason for this is that gastric and gastroesophageal cancers have different anatomic locations and patterns of metastatic spread which may necessitate different surgical and adjunctive treatment approaches (e.g. radiotherapy is more commonly used for proximal tumours). Over the past 2 years, there have been potentially important developments in therapeutics, risk stratification and treatment personalisation relating to peri-operative treatment of this disease. The aim of this review is to highlight recent findings and to contextualise them within current gastroesophageal cancer treatment paradigms.
Peri-operative chemotherapy in evolution
Historical pivotal trials with surgery alone control groups (Medical Research Council Adjuvant Gastric Infusional Chemotherapy and ACCORD07/FFCD) Peri-operative chemotherapy was first established as a standard of care based on the results of two large randomised controlled trials. The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) was a multicentre study in which 503 patients with gastroesophageal adenocarcinoma were randomly assigned to either 9 weeks of pre-and post-operative epirubicin, cisplatin and 5FU (ECF) before surgery or to surgery alone [5] . Peri-operative ECF resulted in a significant improvement in 5-year overall survival (36% versus 23%, P ¼ 0.009) as well as demonstrating a progression-free survival benefit (HR 0.66; 95% CI 0.53-0.81; P < 0.01). Almost identical findings were observed in the French ACCORD07/FFCD 9703 trial [6] . Both trials were pivotal studies that changed the landscape of treatment of gastric cancer and supported the use of multimodal treatment rather than surgery alone. As the ACCORD07/FFCD 9703 trial demonstrated a comparable survival benefit for a platinum doublet compared with an anthracycline containing triplet in MAGIC, a platinum doublet is considered by many to be equally acceptable to anthracycline containing chemotherapy in this setting [11] .
Treatment intensification and anti-angiogenesis (OE05 and ST03)
In order to understand whether intensification of the duration of neoadjuvant chemotherapy or addition of an anthracycline to a cisplatin doublet would improve survival for patients with resectable gastroesophageal junctional or oesophageal adenocarcinoma, the UK Medical Research Council (MRC) OE05 study randomly assigned 897 patients to either 6 weeks of pre-operative 5-FU and cisplatin (as per OE02 study) or 12 weeks of epirubicin, cisplatin and capecitabine (ECX) chemotherapy [15, 16] . Intensification of neoadjuvant chemotherapy was not associated with a significant improvement in median progression-free survival (1.78 versus 1.53 years, P ¼ 0.058) or in overall survival (2.15 versus 2.02 years, P ¼ 0.86). This study resulted in the use of this anthracycline-containing three drug regimen to be considered as a lower level category 2B recommendation by the National Comprehensive Cancer Network in the United States [13] .
Antiangiogenic therapy is associated with improved survival in patients with previously treated metastatic gastroesophageal cancer based on the results of the RAINBOW and REGARD trials, however, did not result in improved overall survival in the first line RAINFALL study [17] [18] [19] . The UK ST03 trial evaluated the benefit of addition of anti-VEGF monoclonal antibody bevacizumab to peri-operative ECX chemotherapy in over 1000 patients with gastroesophageal adenocarcinoma [20] . The addition of bevacizumab did not convey any additional benefit in overall survival (3-year overall survival, ECX 48.9% versus ECX and bevacizumab 47.6%), and was also associated with a higher risk of anastomotic leak in patients who underwent oesophagogastrectomy (9% versus 23%). Therefore, the use of antiangiogenic therapy should remain confined to previously treated patients with advanced gastroesophageal cancer. The results of the UK OE05 and ST03 studies are disappointing; however, OE05 has definitively demonstrated that further dose or schedule intensification of chemotherapy in patients with operable gastroesophageal cancer is unlikely to benefit patients.
A shift in the treatment paradigm: FLOT In contrast to treatment intensification which has failed to provide a survival advantage for patients with operable gastroesophageal cancer, drug substitution using a more effective chemotherapy drug may improve outcomes, as demonstrated in the AIO-FLOT4 study [21] . In this trial, docetaxel and oxaliplatin replaced epirubicin and cisplatin, respectively, in a peri-operative treatment regimen. AIO-FLOT4 compared a standard six cycles of peri-operative ECF/X (ECF or capecitabine) with eight perioperative cycles of a triplet comprised of docetaxel, 5-FU, folinic acid and oxaliplatin (FLOT). Previously, addition of a taxane to cisplatin and 5FU in advanced gastroesophageal cancer had yielded a modest, yet significant benefit in overall survival [22] . The AIO-FLOT4 trial recruited 716 patients with gastric and GOJ adenocarcinoma (56% of patients had GOJ cancer and 44% distal gastric cancer). Patients who were treated with FLOT had a higher rate of curative resection (84% versus 77%, P ¼ 0.01), and prolonged overall survival [HR 0.77 (0.63-0.94) P ¼ 0.012] was observed in FLOT treated patients compared with ECF/ECX, leading to an absolute gain in overall survival of 15 months (median OS 50 versus 35 months ECF/X versus FLOT, respectively, see Table 1 for details). Importantly, there was no increase in surgical morbidity or mortality with FLOT chemotherapy. The most common grade 3 or 4 adverse events were mucositis and neutropenia, which was noted in 52% of patients in the FLOT group versus 38% of patients in the ECF/ECX group; infections were also significantly more common in patients treated with FLOT (18% versus 9%, respectively, P < 0.001, see Table 1 for comparison). Granulocyte colony stimulating factors were not used prophylactically in the trial. Significant (grade 3) sensory neuropathy was also more common in patients treated with FLOT (7% versus 2%, P ¼ 0.002). However, FLOT also caused less nausea and vomiting, thromboembolic disease and anaemia than ECF/X. Despite these variations in toxicity, there were no differences between the arms of the trial in completion of chemotherapy before surgery, serious adverse events related to treatment or in treatment related deaths. Additionally, more patients treated with FLOT started post-operative chemotherapy (60% FLOT versus 52% ECX) which also led to a higher proportion of FLOT treated patients completing all allocated post-operative chemotherapy (46% versus 37%, respectively), suggesting that FLOT might be a more tolerable regimen. Notably, patients over 70 years of age made up 24% of the population in the FLOT trial, implying that FLOT may be a regimen that can be safely administered to older patients. However, caution may be warranted, as higher toxicity rates in older patients receiving peri-operative FLOT have previously been observed [23] .
The AIO-FLOT4 trial has now established FLOT as a new standard of care for suitable patients in the peri-operative chemotherapy management of resectable gastric and gastroesophageal cancer, and conclusively demonstrates the superiority of taxanes compared with anthracyclines in the treatment of gastroesophageal cancer. Using the ESMO-Magnitude of Clinical Benefit Scale version 1.1 for curative therapies, FLOT attains the highest possible score (A) and use of FLOT has been incorporated as a recommendation into international guidelines [11] . However, although FLOT is associated with an improvement in survival for patients with operable disease, several challenges remain. The first challenge is that because estimated 5-year survival for patients treated with FLOT is <50%, ongoing efforts to improve peri-operative treatment are required. The second issue is that although more patients treated with FLOT compared with ECF/X completed all allocated post-operative chemotherapy (46% versus 37%), this still represents less than half of the intention to treat population. Therefore, future efforts might focus on the true value of the adjuvant component of treatment, with an aim to focus on more specific populations who benefit from postoperative treatment, or increase tolerability. On relapse, the optimal treatment to use on relapse for patients who have been treated with peri-operative FLOT is unknown. Time since surgery and the presence of neuropathy might inform whether to re-challenge with a taxane and/or oxaliplatin; cisplatin or irinotecan-based combinations offer alternative options for suitable patients.
Interestingly, in Asia, where adjuvant chemotherapy is the standard of care for resected gastric cancer based on the results of the ACTS-GC and CLASSIC trials, peri-operative chemotherapy is also being evaluated [8, 9, 24, 25] . A neoadjuvant docetaxeloxaliplatin-S1 peri-operative chemotherapy approach followed by adjuvant S1 compared with adjuvant S1 alone has been evaluated in the phase III randomised PRODIGY trial (NCT01515748). A similar study in Japan (JCOG 1509) study will evaluate the role of neoadjuvant S1 plus oxaliplatin plus adjuvant S1 versus adjuvant S1 alone in cT3-4N1-3M0 gastric cancer. These important trials could result in adoption of peri-operative chemotherapy also in Asia.
New findings and trials in neoadjuvant and adjvuant chemoradiotherapy
Convincing evidence that incorporation of pre-operative chemoradiation for Siewert I and II gastroesophageal junctional tumours can improve R0 resection rate was provided by the Dutch CROSS trial [6] . In this study, which included 275 patients with oesophageal and GOJ adenocarcinoma (in addition to 84 squamous cell carcinoma patients), the combination of radiotherapy with 5 weeks of weekly paclitaxel and carboplatin versus surgery alone was compared. In CROSS, patients treated with neoadjuvant chemoradiotherapy had a significant improvement in R0 resection rates (92% versus 69%) and overall survival was also better in the chemoradiation arm (3-year overall survival 58% versus 44%). A recent update to the long-term survival results of the CROSS trial suggests that the incidence of distant metastases is also reduced by chemoradiotherapy for up to 2 years following surgery [HR 0.63 (0.46-0.87), P ¼ 0.0040], indicating that systemic control is also improved by this approach [26] . To date, neoadjuvant chemoradiotherapy has not been directly compared with peri-operative chemotherapy in a randomised controlled trial with an overall survival outcome, and both approaches are currently guideline endorsed treatment options [10, 13] .
One potential benefit of neoadjuvant chemoradiotherapy is a reduction in the rate of (incomplete) R1 resection or margin positivity following surgery. The results of the contemporary OE05 and ST03 trials have raised the question whether preoperative irradiation to improve R0 resection rates is required in patients with tumour involving the gastroesophageal junction [16, 20] . For example, the rate of R1 resection for patients with lower oesophageal tumours was 34% in ST03 and between 30% and 38% in OE05, respectively [16, 20] . In comparison, in AIO-FLOT4, R1 rates were 16% for FLOT4 versus 23% for ECX. This appears superior to the results in ST03 and OE05, although a breakdown of these results by site of tumour is not yet available and may be influenced by the proportion of distal stomach cancers in the trial [21] . As R0 resection is fundamental to long term survival, it may be reasonable to suggest that patients who are at risk for an R1 resection could have had more benefit from a treatment such as radiotherapy which improves local disease control. This is supported by the low rate of R1 resection in CROSS (8%), but the results in CROSS may also have been influenced by the fact that this trial contained 25% radiosensitive squamous cell carcinoma patients, and also excluded patients with T4 or bulky tumours [6] . There may also be confounding variables relating to patient selection, pre-operative tumour stage and operative approach which hinder direct comparison of large peri-operative chemotherapy and chemoradiotherapy studies [27] . Only the results of larger, randomised trials which will directly compare peri-operative chemotherapy versus chemoradiotherapy will adequately address the question of which treatment modality is superior ( Table 2 ). The ESOPEC trial (NCT02509286), in which neoadjuvant chemoradiation according to the CROSS regimen followed by surgery and peri-operative FLOT chemotherapy will be directly compared [28] . Whether the addition of further systemic chemotherapy to neoadjuvant chemoradiotherapy is helpful will be addressed in the international, Australian led TOPGEAR study (NCT01924819) in which patients with operable gastric and gastroesophageal cancer will be treated with either peri-operative chemotherapy including the FLOT regimen (following an amendment from ECX) or with pre-operative chemotherapy and chemoradiation before surgery followed by adjuvant chemotherapy [29] . In contrast to the value which neoadjuvant chemoradiotherapy adds to the treatment of operable gastroesophageal cancer, postoperative chemoradiotherapy in addition to peri-operative chemotherapy does not result in improved long-term survival compared with peri-operative chemotherapy alone. The CRITICS trial was a large (n ¼ 788) randomised trial which evaluated the addition of post-operative radiotherapy (45 Gy in 25) in conjunction with weekly cisplatin and daily capecitabine in resected gastroesophageal cancer patients who were treated with neoadjuvant epirubicin/cisplatin or oxaliplatin and capecitabine chemotherapy [30] . In CRITICS, the control arm received the same post-operative chemotherapy as during the neoadjuvant phase. Five-year survival was equivalent in each arm of the trial [41.3% for chemotherapy and 40.9% for chemoradiotherapy (P ¼ 0.99)]. These results are consistent with the ARTIST and CALGB 80101 studies and suggest that intensification of adjuvant treatment using chemoradiotherapy should be focused on patients at high risk of recurrence such as node positive patients (ARTIST II, NCT01761461) or, in view of the difficulty of delivery of postoperative treatment, might be preferentially delivered before surgery [31] [32] [33] .
Novel concepts: risk stratification and treatment individualisation
Based on the results of the AIO-FLOT4 trial the treatment paradigm is changing in resectable gastroesophageal cancer. For fit patients, taxane-based peri-operative chemotherapy using FLOT will replace anthracycline containing triplets; however, platinumfluoropyrimidine doublet chemotherapy may be used in less fit patients. Importantly, these results and trials do not address the emerging data which suggest that treatment personalisation for patients with gastroesophageal cancer patients may be possible based on selected molecular, radiological and pathological characteristics. Exploration of individualised treatments in these subgroups may be helpful to focus treatment on patients most at risk for disease recurrence, thereby improving survival. These data are discussed in the following section.
Molecular characterisation: mismatch repair deficient gastric cancer
Although the full potential for molecular characterisation of gastric cancer to drive patient treatment has not yet been fulfilled, there are aspects of this which have begun to inform therapy. The Cancer Genome Atlas (TCGA) Research network, carried out a seminal multiplatform analysis of 295 patient samples with gastric adenocarcinoma and identified the presence of four distinct molecular subtypes of gastric cancer: tumours with microsatellite instability (MSI), Epstein-Barr virus associated tumours, chromosomal instability (CIN) and genomically stable tumours [34] . Following this, the recent TCGA analysis of oesophageal cancer has expanded our understanding of these two closely intertwined malignancies [35] . The oesophageal cancer TCGA indicated a strong resemblance between oesophageal adenocarcinoma and the TCGA CIN gastric cancer type, to the extent that these two conditions could be considered a single disease entity. The oesophageal TCGA also clearly distinguished between oesophageal squamous cell cancer and adenocarcinoma, the former being more akin to head and neck neoplasms than oesophageal adenocarcinoma. This confirms that oesophageal squamous and adenocarcinoma patients should not be combined in molecularly unselected trials.
A biological subgroup of interest in the peri-operative setting is patients with MSI-H gastric cancer. Mismatch repair deficiency (MMRD) and MSI are positively prognostic for survival in many cancers, whilst their role as a negative predictor of benefit from adjuvant chemotherapy has been generally accepted in early colorectal cancer [36] . In a recent retrospective analysis of the MAGIC trial, MMRD and MSI-high were found to be associated with a positive prognostic effect in patients treated with surgery alone and a differentially negative prognostic effect in patients treated with chemotherapy [37] . MSI-high status correlated with a good prognosis in surgically treated patients, and whilst patients with microsatellite stable cancer were found to derive benefit from adjuvant chemotherapy, those with MSI-H did not (adjusted hazard ratio: 0.561, 95% CI 0.190-1.654, P ¼ 0.2946). Therefore, determining MSI status pre-operatively could act as a predictive biomarker for patient selection for neoadjuvant chemotherapy. These results were validated in a translational study of the CLASSIC trial, a large Asian randomized controlled study of capecitabine plus oxaliplatin-based adjuvant chemotherapy, which confirmed that only patients with microsatellite stable tumours appeared to benefit from adjuvant chemotherapy [HR MSI 1.877 (95% CI 0.284-12.390); P ¼ 0.5130] [38] . The results from the MAGIC and CLASSIC trials suggest that treatment with peri-operative or adjuvant chemotherapy may not be helpful for patients with MSI-H gastric cancers; however, alternative treatments are yet to be defined. Immuno-oncology therapy with PD-1 inhibitors such as nivolumab and pembrolizumab are effective in gastroesophageal cancer, and more specifically MSI-H cancers are known to respond well to immune checkpoint blockade [39] [40] [41] . As between 8% and 22% of patients with resectable gastric cancer are MSI-H, this is a sizeable subgroup in which biomarker selected neoadjuvant or adjuvant immunotherapy could be explored (Figure 1) [34, 37] . Future research may also focus on other biomarkers associated with sensitivity to immunotherapy such as EBV status which could define complementary groups in whom peri-operative chemotherapy could be avoided.
Tumour regression and lymph node metastases
Several tumour regression grading (TRG) systems exist, which characterise the amount of regressive changes following chemotherapy and which have been shown to have a prognostic role in gastrointestinal tumours including oesophageal, pancreas and colorectal cancer [42] . The most commonly used TRG systems for upper GI cancers include the Mandard and Becker grading systems; previous studies have suggested that TRG could correlate with survival in patients treated with chemotherapy or chemoradiotherapy for gastroesophageal cancers [43, 44] .
A retrospective translational study has evaluated the relationship between Mandard TRG pathological response, lymph node metastases, neoadjuvant ECF chemotherapy and survival in the data obtained in MAGIC trial [45] . The findings of this study indicated that lymph node status in the resection specimen following chemotherapy was an independent predictor of survival post-chemotherapy and resection. Pathological response was prognostic in the univariate but not in the multivariate analysis. Notably, even patients with a poor pathological response to chemotherapy who did not have lymph node metastases had equivalent survival to patients who had an excellent pathological response with no lymph nodes involved in the resection specimen. As survival has been demonstrated to be poor in patients with lymph node metastases (N1), it may be helpful to evaluate whether omitting adjuvant chemotherapy and switching to an alternative regimen in patients with lymph node-positive disease following neoadjuvant chemotherapy will result in improved survival. This approach will be investigated in the EORTC 1707 VESTIGE trial which will randomise patients who are high risk for recurrence (either R1 or N1 status) following neoadjuvant chemotherapy and surgery to either continue with the same adjuvant chemotherapy or to switch to immunotherapy using ipilimumab and nivolumab.
Metabolic imaging and adaptive therapies
A baseline radiology assessment and multidisciplinary review are established prerequisites for excellent treatment in resectable gastroesophageal cancer [11] . 18 F-labelled fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET-CT) is routinely used in the staging of patients with gastric and gastroesophageal cancers and studies have indicated a correlation between response on PET, histopathological response following completion of therapy and patient survival, suggesting that molecular imaging can act as a predictive and prognostic marker [46, 47] . The role of PET-CT in directing a switch in pre-operative chemotherapy has been prospectively evaluated in the phase II CALGB 80803 trial [48] . In this study, 257 patients with resectable T1N1-3M0 or T2-4NanyM0 oesophageal adenocarcinoma underwent a baseline PET-CT scan and were then randomly assigned to receive either modified FOLFOX6 or carboplatin/paclitaxel chemotherapy. Following two to three cycles of chemotherapy, patients underwent repeat scan and if the PET Standardized Uptake Value (SUV) was decreased by more than 35% from baseline then these were deemed as PET responders and continued with the pre-assigned chemotherapy followed by radiation therapy. Non-responders crossed over to receive the alternative chemotherapy regime followed by radiotherapy. The primary end point was pathological complete response (pCR) following surgery. In CALGB 80803 non-responders achieved a pCR rate of 18%, allowing the study to meet its primary end point, as a pCR rate of 5% would have been expected if they had persisted with the original regimen. The MUNICON 2 study had previously suggested that treatment of PET non-responders with radiotherapy would improve response rates and R0 resection, but did not result in improved survival versus historical control in this poor prognosis group [49] . Whether switching to a non-cross resistant chemotherapy regimen will improve systemic disease control and overall survival is of critical; this question may be informed by further follow-up.
The Australasian Gastro-Intestinal Trials Group (AGITG) DOCTOR study used similar criteria with respect to identification of non-responders to preoperative chemotherapy [50] . In DOCTOR non-responding patients were randomised to the addition of docetaxel to cisplatin and 5-FU (DCF) or DCF plus radiotherapy. Encouragingly, R0 resection rates were comparable for non-responders treated with DCF chemotherapy compared with CF responders (64% versus 69%), however, R0 resection rates were further improved by the addition of RT to DCF (94% for RT-DCF treated non-responders). Promisingly, non-responding patients treated with DCF had a complete/extensive pathological response rate of 19%, whereas for patients treated with DCF-RT Figure 1 . Possible future paradigms in peri-operative treatment of gastroesophageal cancer.
this was 63%. With the significant caveat of cross trial comparison and a limited sample size, the pathological response rates associated with DCF plus RT in the DOCTOR study are encouraging and superior to those observed in CROSS for adenocarcinoma patients (24%) [6] . However, DCF plus RT regimen was associated with significant levels of grade 3 and 4 toxicity (23% febrile neutropenia), and although this did not impact on surgery, evaluation of the toxicity of this regimen in larger numbers of patients is required. As with CALGB 80803, these promising results must be validated in terms of survival outcomes.
Developments in of gastroesophageal cancer surgery
Despite improvement in resection rates and peri-operative care, post-operative morbidity and mortality for patients undergoing curative resection for gastroesophageal cancer remains a significant burden. For operable gastric cancer, D2 resection in a high volume centres is a recommended standard of care [11] . Centralization of surgery for gastric and oesophageal cancer patients has now been established to be beneficial even for patients considered to be at low operative risk [51, 52] . Metaanalysis also strongly supports improved long-term survival in patients undergoing oesophagectomy in high volume versus low volume centres (HR ¼ 0.82, 95% CI 0.75-0.90). Following establishment of centralisation of surgery as a standard in operable gastroesophageal cancer, an emerging area of interest is whether selected patients with metastatic disease could benefit from surgical intervention in addition to systemic chemotherapy.
Incorporation of immuno-oncology and targeted therapies
In 2017, the anti-PD-1 antibodies pembrolizumab and nivolumab were licenced in the United States and Japan, respectively, for patients with chemorefractory gastroesophageal cancer. However, as response rates to single agent anti-PD-1 therapy are 12% in PD-L1 unselected patients, single agent anti-PD-1 therapy would not be an appropriate treatment of patients with operable gastroesophageal cancer [40, 53] . The effects of combining pembrolizumab with cisplatin and fluoropyrimidine chemotherapy in advanced gastroesophageal cancer were investigated in the KEYNOTE-059 trial (cohort 2) in which an encouraging response rate of 60% was observed [54] . In perioperative trials, the AIO-FLOT8 DANTE trial will investigate atezolizumab (anti-PD-L1) plus FLOT for patients with operable gastroesophageal cancer and the KEYNOTE 585 trial will evaluate cisplatin-fluoropyrimidine chemotherapy 6 pembrolizumab. The CheckMate 577 (NCT02743494) trial is currently addressing the question of adjuvant nivolumab in resected oesophageal and gastroesophageal junctional patients treated with CROSS type preoperative chemoradiotherapy. In a novel approach, the EORTC 1707 VESTIGE study will investigate whether a switch to immunotherapy with nivolumab plus ipilimumab is superior to continuing chemotherapy in patients with high risk (R1 or N1) resected gastroesophageal cancer. Finally, although trastuzumab has well documented survival benefits in patients with HER2 positive gastroesophageal cancer, integration of anti-HER2 therapy into peri-operative therapy has not yet been achieved [55] . The EORTC INNOVATION study (NCT02205047) is evaluating the efficacy of addition of trastuzumab or trastuzumab plus pertuzumab to peri-operative chemotherapy. Although the JACOB trial was negative for an overall survival benefit in patients with metastatic HER2 positive gastroesophageal cancer, combination pertuzumab plus trastuzumab therapy was associated with improved response rates, which could translate into improved R0 resection rates in patients with operable disease [56] . Additional trials which will report on this issue include the AIO-FLOT6 PETRARCA (NCT02581462) study (FLOT 6 trastuzumab/pertuzumab) and the RTOG 1010 study (NCT01196390) which compared neoadjuvant chemoradiotherapy 6 trastuzumab in operable oesophageal and Siewert type I and II junctional cancers.
Discussion Conclusions
Surgery is the only potentially curative option for most patients with gastroesophageal cancers. Although there is no global gold standard of treatment adjunctive to surgery, peri-operative chemotherapy, neoadjuvant chemoradiotherapy and adjuvant chemotherapy may be used in appropriate populations. For patients treated with peri-operative chemotherapy who are fit for a three-drug regimen FLOT should become the treatment of choice. In future, risk stratification of patients using PET, R1 status, lymph node metastases or MSI may help to personalise treatments towards to those who benefit from it most. Finally, as early benefits of immunotherapy with checkpoint inhibitor blockade emerge, it is hoped combination of immunotherapy with standard treatment paradigms or replacement of these with novel therapies will result in further improvement in survival for patients with operable disease.
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